Matthew H. Bakalar

Point-of-care quantification of blood-borne filarial parasites with a mobile phone microscope

Loa loa microfilariae load in blood can be automatically quantified at the point of care using a mobile phone video microscope. Dial “L” for Loa: Answering the call for mass drug administration Filarial nematodes—tiny, parasitic worms that get into the bloodstream and use humans as hosts—are common in certain regions in Africa. One of these filarial nematodes, Loa loa, the causative agent of loiasis, is not compatible with current ivermectin-based mass drug administration (MDA) programs in the region, which are aimed to eliminate other worms that cause onchocerciasis and lymphatic filariasis. MDA causes severe and often fatal neurological side effects for patients co-infected with L. loa; thus, many MDA programs have been suspended. To resume these ivermectin-based campaigns, D’Ambrosio et al. devised a mobile phone–based strategy for quantifying Loa microfilariae in whole blood and, in turn, excluding those individuals from MDA. The authors’ Loa-counting device comprised a mobile phone camera (as the video microscope) and a custom algorithm for tracking the “wriggling” motion of the microfilaria by quantifying the displacement of red blood cells surrounding the Loa. The entire device was packaged for point-of-care use, including its own “app” for smartphones. When tested on samples from 33 potentially Loa-infected subjects in Cameroon, Africa, the device was 94% specific (compared with microscopy results from thick blood smears) and 100% sensitive for patients about the threshold for severe adverse events (30,000 microfilaria per milliliter of blood). With its ease of use and only a fingerprick of blood, this mobile analytical device could be integrated into MDA programs, answering the call for safe and effective programs in Loa-endemic regions. Parasitic helminths cause debilitating diseases that affect millions of people in primarily low-resource settings. Efforts to eliminate onchocerciasis and lymphatic filariasis in Central Africa through mass drug administration have been suspended because of ivermectin-associated serious adverse events, including death, in patients infected with the filarial parasite Loa loa. To safely administer ivermectin for onchocerciasis or lymphatic filariasis in regions co-endemic with L. loa, a strategy termed “test and (not) treat” has been proposed whereby those with high levels of L. loa microfilariae (>30,000/ml) that put them at risk for life-threatening serious adverse events are identified and excluded from mass drug administration. To enable this, we developed a mobile phone–based video microscope that automatically quantifies L. loa microfilariae in whole blood loaded directly into a small glass capillary from a fingerprick without the need for conventional sample preparation or staining. This point-of-care device automatically captures and analyzes videos of microfilarial motion in whole blood using motorized sample scanning and onboard motion detection, minimizing input from health care workers and providing a quantification of microfilariae per milliliter of whole blood in under 2 min. To validate performance and usability of the mobile phone microscope, we tested 33 potentially Loa-infected patients in Cameroon and confirmed that automated counts correlated with manual thick smear counts (94% specificity; 100% sensitivity). Use of this technology to exclude patients from ivermectin-based treatment at the point of care in Loa-endemic regions would allow resumption/expansion of mass drug administration programs for onchocerciasis and lymphatic filariasis in Central Africa.

A Test-and-Not-Treat Strategy for Onchocerciasis in Loa loa–Endemic Areas

BACKGROUND Implementation of an ivermectin‐based community treatment strategy for the elimination of onchocerciasis or lymphatic filariasis has been delayed in Central Africa because of the occurrence of serious adverse events, including death, in persons with high levels of circulating Loa loa microfilariae. The LoaScope, a field‐friendly diagnostic tool to quantify L. loa microfilariae in peripheral blood, enables rapid, point‐of‐care identification of persons at risk for serious adverse events. METHODS A test‐and‐not‐treat strategy was used in the approach to ivermectin treatment in the Okola health district in Cameroon, where the distribution of ivermectin was halted in 1999 after the occurrence of fatal events related to L. loa infection. The LoaScope was used to identify persons with an L. loa microfilarial density greater than 20,000 microfilariae per milliliter of blood, who were considered to be at risk for serious adverse events, and exclude them from ivermectin distribution. Active surveillance for posttreatment adverse events was performed daily for 6 days. RESULTS From August through October 2015, a total of 16,259 of 22,842 persons 5 years of age or older (71.2% of the target population) were tested for L. loa microfilaremia. Among the participants who underwent testing, a total of 15,522 (95.5%) received ivermectin, 340 (2.1%) were excluded from ivermectin distribution because of an L. loa microfilarial density above the risk threshold, and 397 (2.4%) were excluded because of pregnancy or illness. No serious adverse events were observed. Nonserious adverse events were recorded in 934 participants, most of whom (67.5%) had no detectable L. loa microfilariae. CONCLUSIONS The LoaScope‐based test‐and‐not‐treat strategy enabled the reimplementation of community‐wide ivermectin distribution in a heretofore “off limits” health district in Cameroon and is a potentially practical approach to larger‐scale ivermectin treatment for lymphatic filariasis and onchocerciasis in areas where L. loa infection is endemic. (Funded by the Bill and Melinda Gates Foundation and others.)Background Implementation of ivermectin-based community treatment for onchocerciasis or lymphatic filariasis elimination has been delayed in Central Africa because of severe adverse events (SAEs), including death, in people with high levels of circulating Loa loa microfilariae (mf). LoaScope, a rapid field-friendly diagnostic tool to quantify L. loa mf in peripheral blood, permits point-of-care identification of individuals “at risk” for SAEs. Methods A “Test and not Treat” (TaNT) strategy was used to implement ivermectin treatment in the Okola health district in Cameroon, where ivermectin distribution was halted in 1999 after the occurrence of fatal Loa-related SAEs. The LoaScope was used to identify and exclude individuals with >20,000 mf per milliliter of blood (at-risk for SAEs) from ivermectin treatment. Active surveillance for post-treatment adverse events (AEs) was conducted daily for 7 days. Results Between August and October 2015, 16,259 (71.1%) individuals >=5 years of age were tested out of a target population of ~22,800. Among the ivermectin-eligible population, 15,522 (95.5%) received ivermectin; 340 (2.1%) were excluded from ivermectin treatment because of a L. loa density above the risk-threshold and 397 (2.4%) were excluded for pregnancy or illness. No SAEs were observed. Non-severe AEs were recorded in 934 individuals, most (67%) of whom had no detectable L. loa mf. Conclusions The LoaScope-based TaNT strategy permitted safe re-implementation of community-wide ivermectin distribution in a heretofore ‘off limits’ health district in Cameroon and is an extremely promising and practical approach for large-scale ivermectin treatment for lymphatic filariasis and onchocerciasis elimination in Loa loa-endemic areas.

Correlation analysis framework for localization-based superresolution microscopy

Significance Correlation analysis is one of the most widely used image-processing methods. In the quantitative analysis of localization-based superresolution images, there still lacks a generalized coordinate-based correlation analysis framework to take full advantage of the superresolution information. We propose a coordinate-based correlation analysis framework for localization-based superresolution microscopy. We mathematically prove that point-point distance distribution is equivalent to pixel-based correlation function. This framework can be easily extended to model the effect of localization uncertainty, to the time domain and other distance definitions. We demonstrated the versatility and advantages of our framework in three applications of superresolution microscopy: model-free image alignment and averaging for structural analysis, spatiotemporal correlation analysis for mapping molecule diffusion, and quantifying spatial relationships between complex structures. Superresolution images reconstructed from single-molecule localizations can reveal cellular structures close to the macromolecular scale and are now being used routinely in many biomedical research applications. However, because of their coordinate-based representation, a widely applicable and unified analysis platform that can extract a quantitative description and biophysical parameters from these images is yet to be established. Here, we propose a conceptual framework for correlation analysis of coordinate-based superresolution images using distance histograms. We demonstrate the application of this concept in multiple scenarios, including image alignment, tracking of diffusing molecules, as well as for quantification of colocalization, showing its superior performance over existing approaches.

In Southern Nigeria Loa loa Blood Microfilaria Density is Very Low Even in Areas with High Prevalence of Loiasis: Results of a Survey Using the New LoaScope Technology

Ivermectin treatment can cause central nervous system adverse events (CNS-AEs) in persons with very high-density Loa loa microfilaremia (≥ 30,000 mf/mL blood). Hypoendemic onchocerciasis areas where L. loa is endemic have been excluded from ivermectin mass drug administration programs (MDA) because of the concern for CNS AEs. The rapid assessment procedure for L. loa (RAPLOA) is a questionnaire survey to assess history of eye worm. If ≥ 40% of respondents report eye worm, this correlates with ≥ 2% prevalence of very high-density loiasis microfilaremia, posing an unacceptable risk of CNS-AEs after MDA. In 2016, we conducted a L. loa study in 110 ivermectin-naïve, suspected onchocerciasis hypoendemic villages in southern Nigeria. In previous RAPLOA surveys these villages had prevalences between 10% and 67%. We examined 10,605 residents using the LoaScope, a cell phone-based imaging device for rapidly determining the microfilaria (mf) density of L. loa infections. The mean L. loa village mf prevalence was 6.3% (range 0-29%) and the mean individual mf count among positives was 326 mf/mL. The maximum individual mf count was only 11,429 mf/mL, and among 2,748 persons sampled from the 28 villages with ≥ 40% RAPLOA, the ≥ 2% threshold of very high Loa mf density could be excluded with high statistical confidence (P < 0.01). These findings indicate that ivermectin MDA can be delivered in this area with extremely low risk of L. loa-related CNS-AEs. We also concluded that in Nigeria the RAPLOA survey methodology is not predictive of ≥ 2% prevalence of very high-density L. loa microfilaremia.